For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
A comparison of monoclonal antibody clones against PD-L1
In order to give you the best chance of finding the optimal PD-L1 clone for your research assay, you can now get access to four key recombinant monoclonal PD-L1 antibody clones from Abcam (73-10, 28-8, SP142 and CAL10), as well as the anti-mouse recombinant rabbit monoclonal EPR20529 and the mouse monoclonal PDL1/2746.
PD-L1 (also known as B7-H1, CD274) is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies (additional details here).
It is therefore vital to have reliable and reproducible tools to detect and measure PD-L1. You can now access all 4 anti-human recombinant rabbit monoclonal antibody clones in our trial size panel kit.
|Product name||Clone 28-8||Clone 73-10||Clone SP142||Clone EPR20529||Clone CAL10||Clone PDL1/2746|
|Host/Clonality||Rabbit monoclonal||Rabbit monoclonal||Rabbit monoclonal||Rabbit monoclonal||Rabbit monoclonal||Mouse monoclonal|
|Species reactivity||Human||Human||Human||Mouse||Human||Mouse, human|
|Applications verified||IHC-P, ICC/IF, flow cytometry, WB||IHC-P, WB, ICC/IF, WB, flow cytometry, ELISA||IHC-P, ICC/IF, IP, WB||ICC/IF, IP, WB||IHC-P||IHC-P, ICC/IF, WB, flow cytometry|
|Ideal usage||IHC autostainer||IHC autostainer||ICC human||ICC mouse||IHC autostainer||Multiplexing|
Independent studies have compared the performance of IVD grade/diagnostic PD-L1 IHC assay kits. The blueprint phase 2 project used the IVD grade/diagnostic IHC assays 73-10 (Dako/Agilent), 28-8 (Dako) and SP142 (Ventana), and the Karnik paper used 22C3 (Dako), SP263 (Ventana) and CAL10 (BioCare). See the links below to read the findings.